SAN DIEGO--(BUSINESS WIRE)--A novel formulation of diclofenac provides pain relief at lower-than-standard doses during a Phase II clinical study as reported today at the 2011 World Congress on Osteoarthritis.1 The Congress is organized by the Osteoarthritis Research Society International.
